Related Experiment Video

Updated: Apr 1, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer

Mahdi Shabani, Mohammad Hojjat-Farsangi1

  • 1Department of Oncology- Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.

Current Drug Targets
|October 2, 2015
PubMed

Insights

Monoclonal antibodies (mAbs) offer a promising strategy for targeting oncogenic receptor tyrosine kinases (RTKs) in cancer therapy. These highly specific agents are crucial for developing personalized medicine approaches against various malignancies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Immunology

Background:

  • Receptor tyrosine kinases (RTKs) are cell surface glycoproteins regulating critical cellular functions like proliferation, differentiation, and survival.
  • Dysregulation of over 30 RTKs is implicated in the development and progression of various human cancers.
  • Targeting RTKs represents a key strategy in developing novel cancer therapies.

Purpose of the Study:

  • To review recent advancements in the development of monoclonal antibodies (mAbs) targeting oncogenic RTKs.
  • To highlight the potential of mAbs in personalized medicine for cancer treatment.
  • To discuss the application of mAbs in targeting RTKs for both malignancies and autoimmune disorders.

Main Methods:

  • Review of current literature on monoclonal antibodies targeting receptor tyrosine kinases.
  • Analysis of the role of RTKs in cancer development and progression.
  • Evaluation of the specificity and therapeutic potential of mAbs in preclinical and clinical settings.

Main Results:

  • Monoclonal antibodies (mAbs) demonstrate high specificity for targeting RTKs expressed on tumor cell surfaces.
  • The development and approval of mAbs for therapeutic use are rapidly increasing.
  • mAbs are effective in interfering with molecular pathways essential for tumor growth and survival.

Conclusions:

  • Targeted therapies using mAbs against oncogenic RTKs are a promising approach for cancer treatment.
  • The high specificity of mAbs makes them ideal candidates for personalized medicine strategies.
  • Further development and application of RTK-targeting mAbs are expected in oncology and autoimmune diseases.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.8K